Purpose: To determine if a series of trials with fraction of inspired oxygen (FiO2) content deception could improve 4000-m cycling time-trial (TT) performance. Methods: A total of 15 trained male cyclists (mean [SD] body mass 74.2 [8.0] kg, peak oxygen uptake 62  mL·kg−1·min−1) completed six 4000-m cycling TTs in a semirandomized order. After a familiarization TT, cyclists were informed in 2 initial trials they were inspiring normoxic air (NORM, FiO2 0.21); however, in 1 trial (deception condition), they inspired hyperoxic air (NORM-DEC, FiO2 0.36). During 2 subsequent TTs, cyclists were informed they were inspiring hyperoxic air (HYPER, FiO2 0.36), but in 1 trial, normoxic air was inspired (HYPER-DEC). In the final TT (NORM-INFORM), the deception was revealed and cyclists were asked to reproduce their best TT performance while inspiring normoxic air. Results: Greater power output and faster performances occurred when cyclists inspired hyperoxic air in both truthful (HYPER) and deceptive (NORM-DEC) trials than NORM (P < .001). However, performance only improved in NORM-INFORM (377 W; 95% confidence interval [CI] 325–429) vs NORM (352 W; 95% CI 299–404; P < .001) when participants (n = 4) completed the trials in the following order: NORM-DEC, NORM, HYPER-DEC, HYPER. Conclusions: Cycling performance improved with acute exposure to hyperoxia. Mechanisms for the improvement were likely physiological; however, improvement in a deception trial suggests an additional placebo effect. Finally, a particular sequence of oxygen deception trials may have built psychophysiological belief in cyclists such that performance improved in a subsequent normoxic trial.
Michael J. Davies, Bradley Clark, Laura A. Garvican-Lewis, Marijke Welvaert, Christopher J. Gore and Kevin G. Thompson
Andrew J.R. Cochran, Michael E. Percival, Sara Thompson, Jenna B. Gillen, Martin J. MacInnis, Murray A. Potter, Mark A. Tarnopolsky and Martin J. Gibala
Sprint interval training (SIT), repeated bouts of high-intensity exercise, improves skeletal muscle oxidative capacity and exercise performance. β-alanine (β-ALA) supplementation has been shown to enhance exercise performance, which led us to hypothesize that chronic β-ALA supplementation would augment work capacity during SIT and augment training-induced adaptations in skeletal muscle and performance. Twenty-four active but untrained men (23 ± 2 yr; VO2peak = 50 ± 6 mL·kg−1·min−1) ingested 3.2 g/day of β-ALA or a placebo (PLA) for a total of 10 weeks (n = 12 per group). Following 4 weeks of baseline supplementation, participants completed a 6-week SIT intervention. Each of 3 weekly sessions consisted of 4–6 Wingate tests, i.e., 30-s bouts of maximal cycling, interspersed with 4 min of recovery. Before and after the 6-week SIT program, participants completed a 250-kJ time trial and a repeated sprint test. Biopsies (v. lateralis) revealed that skeletal muscle carnosine content increased by 33% and 52%, respectively, after 4 and 10 weeks of β-ALA supplementation, but was unchanged in PLA. Total work performed during each training session was similar across treatments. SIT increased markers of mitochondrial content, including cytochome c oxidase (40%) and β-hydroxyacyl-CoA dehydrogenase maximal activities (19%), as well as VO2peak (9%), repeated-sprint capacity (5%), and 250-kJ time trial performance (13%), but there were no differences between treatments for any measure (p < .01, main effects for time; p > .05, interaction effects). The training stimulus may have overwhelmed any potential influence of β-ALA, or the supplementation protocol was insufficient to alter the variables to a detectable extent.
Lauren T. Ptomey, Eric D. Vidoni, Esteban Montenegro-Montenegro, Michael A. Thompson, Joseph R. Sherman, Anna M. Gorczyca, Jerry L. Greene, Richard A. Washburn and Joseph E. Donnelly
Adults with Alzheimer’s disease (AD) and their caregivers represent a segment of the population with low levels of moderate-intensity physical activity (MPA) and limited options for increasing MPA. The purpose of this study was to evaluate the feasibility of a group video conference approach for increasing MPA in adults with AD and their caregivers. Adults with AD and their caregivers attended 30-min group exercise sessions three times per week for 12 weeks. Exercise sessions and support sessions were delivered in their homes on a tablet computer over video conferencing software. Nine adults with AD/caregiver dyads enrolled, and seven completed the 12-week intervention. Adults with AD attended 77.3% of the group exercise sessions, and caregivers attended 79.2% of group exercise sessions. Weekly MPA increased in both adults with AD (49%) and caregivers (30%). Exercise delivered by group video conferencing is a feasible and potentially effective approach for increasing MPA in adults with AD and their caregivers.